We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

HTG Introduces ArrayPlate Testing Method
Product News

HTG Introduces ArrayPlate Testing Method

HTG Introduces ArrayPlate Testing Method
Product News

HTG Introduces ArrayPlate Testing Method

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "HTG Introduces ArrayPlate Testing Method"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

HTG, Inc. has announced the availability of an ArrayPlate to measure four genes in each well of a 384-well plate for high throughput screening and profiling.

The ArrayPlate 384-4 is designed to enable researchers in the pharmaceutical and biotechnology industries to quantify RNA expression levels in cells treated with potential new drugs with high sample throughput, 10,000 or more samples per hour, and whole assay CV's of less than 10%.

The ArrayPlate 384-4 platform offering is based on HTG's self-customized quantitative Nuclease Protection Assay (qNPA™) technology, which allows researchers to test any sample type, including fixed tissue, using small sample sizes while avoiding the need for extraction, reverse transcription or amplification.

The technology is designed to provide the absolute sensitivity to measure any gene desired, including low abundant genes.

Instead of studying one gene at a time, researchers are also able to select a set of genes for simultaneous evaluation, a critical step in identifying the most promising drug compounds to treat complex, multi-factorial diseases.

Researchers can further utilize the 384-4 multiplexing capabilities by exploiting the power of gene signatures to reduce the whole cell assay false positive rate significantly, to as little as 0.05 percent, permitting discovery of weakly active compounds that would otherwise be missed.

The platform is designed to provide sensitive and quantitative test results, including QSAR-quality dose response data and EC(50)'s, enabling clients to profile and optimize leads, compress drug discovery and development program timelines.

The ArrayPlate 384-4 consists of a user-customizable plate with four elements of anchor oligonucleotides printed at the bottom of each well of the plate which allows researchers to measure up to four genes of their choice per well.

This provides researchers with 1536 data points per plate. Combined with the ability to fully automate qNPA using off-the-shelf automation hardware, the ArrayPlate 384-4 technology permits the acquisition of 40,000 or more discrete gene measurements per hour.

"HTG's ArrayPlate 384-4 technology enables high throughput screening at the level of gene expression, offering researchers a quick, easy and reliable method to economically and efficiently test more samples faster to address the issue the industry has faced with whole cell assay false positive rates," said Bruce Seligmann, CSO, HTG.

"Combined with qNPA QSAR capabilities, complete gene expression-based drug discovery programs can now be pursued from high throughput screening through in vitro and in vivo lead optimization."

"We are committed to developing and manufacturing highly sensitive and reproducible testing methods to help researchers wade through the growing amount of information available in the quest for new drug therapies."